FDA accepts for priority review Biologics License Application for Valrox (valoctocogene roxaparvovec), a gene therapy for Haemophilia A

Currently patients with haemophilia A are treated with factor VIII, two to three times a week. Valrox is a potential gene therapy that is administered as a single infusion. Ongoing phase III trial hopes tvalrox will prove to be superior to factor VIII replacement therapy.

SPS commentary:

A licensing application was submitted in EU in November 2019 for treatment of adults with severe haemophilia A.


Biospace Inc.